• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Brad Perriello

SteadyMed sets terms for $55m IPO

March 10, 2015 By Brad Perriello

SteadyMed sets terms for $55m IPO

SteadyMed Therapeutics yesterday set the terms for its pending debut on the public market, saying it plans to float 4.25 million shares at $12 to $14 apiece.

Filed Under: Drug-Device Combinations Tagged With: SteadyMed Therapeutics

Bellerophon prices $60m IPO low, issues more shares

February 13, 2015 By Brad Perriello

Bellerophon prices $60m IPO low, issues more shares

Filed Under: Drug-Device Combinations Tagged With: Bellerophon Therapeutics

Diabetes: Intarcia inks $1B development deal with Servier

November 12, 2014 By Brad Perriello

Diabetes: Intarcia inks $1B development deal with Servier

Intarcia Therapeutics said today that French pharmaceutical independent Servier agreed to a deal to commercialize Intarcia’s implantable diabetes pump that could be worth some $1 billion.

Filed Under: Drug-Device Combinations Tagged With: Intarcia Therapeutics, Servier

Fresenius ends Russia joint venture, feels impact of Ukraine crisis

November 7, 2014 By Brad Perriello

Fresenius ends Russia joint venture, feels impact of Ukraine crisis

Filed Under: Drug-Device Combinations Tagged With: Fresenius Medical Care

Shareholders lawsuit against Unilife fizzles

January 23, 2014 By Brad Perriello

Shareholders lawsuit against Unilife fizzles

The plaintiff in a purported class action shareholders lawsuit against Unilife (NSDQ:UNIS) voluntarily withdrew the complaint after no other stockholders stepped up to join the suit.

Filed Under: Drug-Device Combinations Tagged With: Unilife Corp.

pSivida gains big on buyout rumor

June 19, 2013 By Brad Perriello

pSivida gains big on buyout rumor

Shares of ophthalmology company pSivida (NSDQ:PSDV) hit a 52-week high today on speculation from a Seeking Alpha blogger that it’s ripe for an acquisition this year.

PSDV shares hit $3.96 each today, a 52-week high, having gained some 15.5% since a blogger writing as "Bob’s Stocks" published the rumor yesterday.

Filed Under: Drug-Device Combinations Tagged With: pSivida Corp.

Baxter buys stake in Ocular Therapeutix

June 10, 2013 By Brad Perriello

Baxter buys stake in Ocular Therapeutix

Baxter‘s (NYSE:BAX) venture capital arm bought a minority stake in Ocular Therapeutix and its slate of ophthalmic products, part of an $8.5 million funding round that also included existing backer Ascension Health Ventures.

Filed Under: Drug-Device Combinations Tagged With: Ascension Health Ventures, Baxter International, Ocular Therapeutix Inc

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 12
  • Page 13
  • Page 14

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS